A side-by-side reading of CJC-1295 and Ipamorelin from our profiles: origin, mechanism, studied uses and evidence status. No recommendations — only what the sources say.
Key parameters side by side
Parameter
CJC-1295
Ipamorelin
Category
Growth Hormone
Growth Hormone
Evidence status
Preclinical
Clinical Trial
Sequence length
—
—
Molecular weight
3647.28 Da
711.85 Da
Growth Hormone
CJC-1295
Preclinical
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, also known as GRF) designed with enhanced metabolic stability and prolonged duration of action. Developed by ConjuChem Biotechnologies, it is a modified version of the first 29 amino acids of GHRH (GRF 1-29) with four amino acid substitutions that confer DPP-4 resistance and improved receptor binding.
The most widely studied version, CJC-1295 DAC (Drug Affinity Complex), incorporates a reactive maleimidopropionic acid linker that forms a covalent bond with serum albumin after injection. This albumin conjugation extends the half-life from minutes (native GHRH) to approximately 6-8 days, enabling sustained elevation of growth hormone and IGF-1 levels with once or twice-weekly dosing.
CJC-1295 stimulates GH release through the GHRH receptor (GHRH-R) on pituitary somatotrophs, increasing both the amplitude and duration of natural GH pulses while preserving pulsatile secretion patterns. It is frequently combined with GH secretagogues (ipamorelin, GHRP-2) for synergistic effects.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone (GH) release from the anterior pituitary gland by acting as an agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Developed by Novo Nordisk in the late 1990s, it is considered one of the most selective GH secretagogues available, distinguished by its clean pharmacological profile with minimal effects on cortisol, prolactin, and appetite.
Unlike earlier growth hormone secretagogues such as GHRP-6 and GHRP-2, ipamorelin does not significantly stimulate ACTH, cortisol, or prolactin release at GH-stimulating doses — a selectivity that results from its specific binding characteristics at the GHS-R1a receptor. It produces a dose-dependent, pulsatile release of growth hormone that closely mimics the physiological GH secretion pattern.
Ipamorelin has undergone Phase 2 clinical trials for post-operative ileus recovery and continues to be researched for applications in age-related GH decline, body composition improvement, and recovery from injury. It is frequently combined with GHRH analogs (CJC-1295, Mod GRF 1-29) for synergistic GH release.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, also known as GRF) designed with enhanced metabolic stability and prolonged duration of action. Developed by ConjuChem Biotechnologies, it is a modified version of the first 29 amino acids of GHRH (GRF 1-29) with four amino acid substitutions that confer DPP-4 resistance and improved receptor binding.
The most widely studied version, CJC-1295 DAC (Drug Affinity Complex), incorporates a reactive maleimidopropionic acid linker that forms a covalent bond with serum albumin after injection. This albumin conjugation extends the half-life from minutes (native GHRH) to approximately 6-8 days, enabling sustained elevation of growth hormone and IGF-1 levels with once or twice-weekly dosing.
CJC-1295 stimulates GH release through the GHRH receptor (GHRH-R) on pituitary somatotrophs, increasing both the amplitude and duration of natural GH pulses while preserving pulsatile secretion patterns. It is frequently combined with GH secretagogues (ipamorelin, GHRP-2) for synergistic effects.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone (GH) release from the anterior pituitary gland by acting as an agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a). Developed by Novo Nordisk in the late 1990s, it is considered one of the most selective GH secretagogues available, distinguished by its clean pharmacological profile with minimal effects on cortisol, prolactin, and appetite.
Unlike earlier growth hormone secretagogues such as GHRP-6 and GHRP-2, ipamorelin does not significantly stimulate ACTH, cortisol, or prolactin release at GH-stimulating doses — a selectivity that results from its specific binding characteristics at the GHS-R1a receptor. It produces a dose-dependent, pulsatile release of growth hormone that closely mimics the physiological GH secretion pattern.
Ipamorelin has undergone Phase 2 clinical trials for post-operative ileus recovery and continues to be researched for applications in age-related GH decline, body composition improvement, and recovery from injury. It is frequently combined with GHRH analogs (CJC-1295, Mod GRF 1-29) for synergistic GH release.